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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to silicon 
and protection against aluminium accumulation in the brain (ID 290), 
“cardiovascular health” (ID 289), forming a protective coat on the mucous 
membrane of the stomach (ID 345), neutralisation of gastric acid (ID 345), 
contribution to normal formation of collagen and connective tissue (ID 287, 
288, 333, 334, 335, 1405, 1652, 1718, 1719, 1945), maintenance of normal 
bone (ID 287, 335, 1652, 1718, 1945), maintenance of normal joints 
(ID 1405, 1652, 1945), maintenance of normal appearance and elasticity of 
the skin (ID 288, 333), and contribution to normal formation of hair and 
nails (ID 334, 1652, 1719) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to silicon and protection against aluminium accumulation in the brain, cardiovascular 
health, forming a protective coat on the mucous membrane of the stomach, neutralisation of gastric 
acid, contribution to normal formation of collagen and connective tissue, maintenance of normal 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1074, EFSA-Q-2008-1075, EFSA-Q-2008-1076, 
EFSA-Q-2008-1077, EFSA-Q-2008-1120, EFSA-Q-2008-1121, EFSA-Q-2008-1122, EFSA-Q-2008-1132, 
EFSA-Q-2008-2142, EFSA-Q-2008-2388, EFSA-Q-2008-2454, EFSA-Q-2008-2455, EFSA-Q-2008-2678, adopted on 
25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Bone/Teeth/Connective Tissue: Rikke Andersen, Olivier Bruyère, Albert Flynn, Ingegerd Johansson, Jukka Meurman 
and Hildegard Przyrembel. The members of the Claims Sub-Working Group on Mental/Nervous System: Jacques Rigo, 
Astrid Schloerscheidt, Barbara Stewart-Knox, Sean (J.J.) Strain, and Peter Willatts.  
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bone, maintenance of normal joints, maintenance of normal appearance and elasticity of the skin, and 
contribution to normal formation of hair and nails. The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claims is silicon. The Panel considers that silicon 
is sufficiently characterised. 
Protection against aluminium accumulation in the brain 
The claimed effect is “mental health”. The target population is assumed to be the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to protection 
against aluminium accumulation in the brain. The Panel considers that protection against aluminium 
accumulation in the brain might be a beneficial physiological effect. 
No human studies were provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of silicon and protection against aluminium accumulation 
in the brain. 
“Cardiovascular health” 
The claimed effect is “cardiovascular health”. The target population is assumed to be the general 
population. The claimed effect is not sufficiently defined and no further details were provided in the 
proposed wording. No further clarifications were provided by Member States.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
Forming a protective coat on the mucous membrane of the stomach  
The claimed effect is “gut health”. The target population is assumed to be the general population. 
From the clarifications provided by Member States, the Panel assumes that the claimed effect refers to 
forming a protective coat on the mucous membrane of the stomach. The Panel considers that forming 
a protective coat on the mucous membrane of the stomach is not a beneficial physiological effect 
per se, but needs to be linked to a beneficial physiological or clinical outcome. The Panel considers 
that no evidence has been provided to indicate in which context the claimed effect could be 
considered to be a beneficial physiological effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of silicon and a beneficial physiological effect related to 
forming a protective coat on the mucous membrane of the stomach. 
Neutralisation of gastric acid 
The claimed effect is “gut health”. The target population is assumed to be the general population. 
From the clarifications provided by Member States, the Panel assumes that the claimed effect refers to 
the neutralisation of gastric acid. The Panel considers that the evidence provided does not establish 
that the neutralisation of gastric acid is a beneficial physiological effect for the general population.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of silicon and a beneficial physiological effect for the 
general population related to the neutralisation of gastric acid. 
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Contribution to normal formation of collagen and connective tissue  
The claimed effects are “silicon is required for normal bone and connective tissue formation”, 
“normal skin, hair and nails”, “maintenance and promotion of healthy connective tissue in skin by 
stimulating collagen synthesis in the dermis”, “helps support hair quality by helping to maintain 
healthy connective tissue in the dermis”, “maintenance and promotion of healthy connective tissue in 
bone by stimulating bone collagen synthesis”, “stability of the connective/cell tissue; strengthening 
the joint cartilage and the intervertebral disks, protection against”, “essential part of the connective 
tissues, skin and hair”, “maintenance and promotion of healthy connective tissue in bone by 
stimulating bone collagen synthesis, healthy women and men”, “helps support hair quality by helping 
to maintain healthy connective tissue in the dermis, healthy women and men”, and “bioavailable 
silicon form, silicon is an essential element for normal structure of connective tissues such as skin, 
hair, joints, bone and blood vessels”. The target population is assumed to be the general population. In 
the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to contribution to normal formation of collagen and connective 
tissue. The Panel considers that contribution to normal formation of collagen and connective tissue is 
a beneficial physiological effect.  
No human studies which addressed the effects of silicon intake on collagen or connective tissue 
formation have been provided. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of silicon and contribution to normal formation of collagen 
or connective tissue. 
Maintenance of normal bone  
The claimed effects are “silicon is required for normal bone and connective tissue formation”, 
“maintenance and promotion of healthy connective tissue in bone by stimulating bone collagen 
synthesis”, “essential part of the connective tissues, skin and hair”, “maintenance and promotion of 
healthy connective tissue in bone by stimulating bone collagen synthesis, healthy women and men”, 
and “bioavailable silicon form, silicon is an essential element for normal structure of connective 
tissues such as skin, hair, joints, bone and blood vessels”. The target population is assumed to be the 
general population. In the context of the proposed wordings, the Panel assumes that the claimed 
effects refer to the maintenance of normal bone. The Panel considers that maintenance of normal bone 
is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that a randomised, double-blind, 
placebo-controlled, human intervention study did not show an effect of silicon administration (as ch-
OSA) on bone mineral density at any site in post-menopausal women, that the findings of a cross-
sectional study on the association between silicon intakes and bone mineral density were inconsistent, 
and that no evidence for a mechanism by which silicon could exert the claimed effect has been 
provided. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of silicon and maintenance of normal bone.  
Maintenance of normal joints 
The claimed effects are “stability of the connective/cell tissue; strengthening the joint cartilage and 
the intervertebral disks, protection against”, “essential part of the connective tissues, skin and hair”, 
and “bioavailable silicon form, silicon is an essential element for normal structure of connective 
tissues such as skin, hair, joints, bone and blood vessels”. The target population is assumed to be the 
general population. In the context of the proposed wordings, the Panel assumes that the claimed 
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effects refer to the maintenance of normal joints. The Panel considers that maintenance of normal 
joints is a beneficial physiological effect. 
No human studies which addressed the effects of silicon withdrawal or silicon intake on joint function 
have been provided.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of silicon and maintenance of normal joints. 
Maintenance of normal appearance and elasticity of the skin 
The claimed effects are “normal skin, hair and nails” and “maintenance and promotion of healthy 
connective tissue in skin by stimulating collagen synthesis in the dermis”. The target population is 
assumed to be the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal appearance and elasticity of the skin. The Panel notes that the evidence 
provided does not establish that changes in the appearance or elasticity of the skin relate to changes in 
skin function.  
The Panel considers that the claim does not refer to a function of the body as required by Regulation 
(EC) No 1924/2006. 
Contribution to normal formation of hair and nails 
The claimed effects are “helps support hair quality by helping to maintain healthy connective tissue in 
the dermis”, “essential part of the connective tissues, skin and hair”, and “helps support hair quality 
by helping to maintain healthy connective tissue in the dermis, healthy women and men”. The target 
population is assumed to be the general population. In the context of the proposed wordings, the Panel 
assumes that the claimed effects refer to the contribution to normal formation of hair and nails. The 
Panel considers that contribution to normal formation of hair and nails is a beneficial physiological 
effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of silicon and contribution to normal formation of hair and 
nails. 
KEY WORDS 
Silicon, aluminium, cardiovascular, stomach, collagen, connective tissue, bone, joints, skin, hair, nails, health 
claims.  
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituents that are the subjects of the health claims are “silicon”, “silicon (as stabilised 
oligomeric orthosilicic acid (OSA))”, “choline-stabilised orthosilicic acid (ch-OSA)”, “Mineral-
wasser/Kieselsäure (Silizium)”, “silica/silicious earth”, and “monométhylsilanetriol”. 
From the references and conditions of use provided in relation to the health claims considered in this 
opinion, the Panel assumes that the food constituent under evaluation is silicon. 
Silicon is authorised for addition to foods (Annex I of Regulation (EC) No 1925/2006
6
 and Annex I of 
Directive 2002/46/EC
7
). This evaluation applies to silicon naturally present in foods and added to 
foods. 
Silicon occurs naturally in foods as silicon dioxide (silica, SiO2) and silicates, and may also be added 
to foods as an anti-caking and anti-foaming agent in the form of silica, silicates and 
dimethylpolysiloxane. Silicate-containing antacids have been widely used for a number of decades.  
Orthosilicic acid [Si(OH)4] or mono-silicic acid is a water soluble form of silicon. A saturated 
solution contains 0.1 % silicic acid. Silicic acid can also exist as an oligomer and as polysilicic acid 
(EFSA, 2004). Oligomeric silica (oligomeric orthosilicic acid) is formed as a meta-stable intermediate 
in the progressive polymerisation of silicic acid in saturated solutions. Monomethylsilanetriol, also 
called organic silicon (CH3-Si-(OH)3), and choline-stabilised orthosilicic acid (ch-OSA) are usually 
added to food supplements as a source of silicon (EFSA, 2009a, 2009b). 
The Panel considers that the food constituent, silicon, which is the subject of the health claims, is 
sufficiently characterised. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
7  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
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2. Relevance of the claimed effect to human health 
2.1. Protection against aluminium accumulation in the brain (ID 290) 
The claimed effect is “mental health”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to protection 
against aluminium accumulation in the brain. 
The Panel considers that protection against aluminium accumulation in the brain might be a beneficial 
physiological effect. 
2.2. “Cardiovascular health” (ID 289) 
The claimed effect is “cardiovascular health”. The Panel assumes that the target population is the 
general population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No further clarifications were provided by Member States. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
2.3. Forming a protective coat on the mucous membrane of the stomach (ID 345) 
The claimed effect is “gut health”. The Panel assumes that the target population is the general 
population. 
From the clarifications provided by Member States, the Panel assumes that the claimed effect refers to 
forming a protective coat on the mucous membrane of the stomach. 
The Panel considers that forming a protective coat on the mucous membrane of the stomach is not a 
beneficial physiological effect per se, but needs to be linked to a beneficial physiological or clinical 
outcome. The Panel notes that no evidence has been provided to indicate the context in which the 
claimed effect could be considered to be a beneficial physiological effect.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of silicon and a beneficial physiological effect related to forming a protective coat on the 
mucous membrane of the stomach.  
2.4. Neutralisation of gastric acid (ID 345) 
The claimed effect is “gut health”. The Panel assumes that the target population is the general 
population. 
From the clarifications provided by Member States, the Panel assumes that the claimed effect refers to 
the neutralisation of gastric acid. 
The Panel considers that the evidence provided does not establish that the neutralisation of gastric 
acid is a beneficial physiological effect for the general population.  
Silicon related health claims 
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The Panel concludes that a cause and effect relationship has not been established between the 
consumption of silicon and a beneficial physiological effect for the general population related to the 
neutralisation of gastric acid. 
2.5. Contribution to normal formation of collagen and connective tissue (ID 287, 288, 333, 
334, 335, 1405, 1652, 1718, 1719, 1945) 
The claimed effects are “silicon is required for normal bone and connective tissue formation”, 
“normal skin, hair and nails”, “maintenance and promotion of healthy connective tissue in skin by 
stimulating collagen synthesis in the dermis”, “helps support hair quality by helping to maintain 
healthy connective tissue in the dermis”, “maintenance and promotion of healthy connective tissue in 
bone by stimulating bone collagen synthesis”, “stability of the connective/cell tissue; strengthening 
the joint cartilage and the intervertebral disks, protection against”, “essential part of the connective 
tissues, skin and hair”, “maintenance and promotion of healthy connective tissue in bone by 
stimulating bone collagen synthesis, healthy women and men”, “helps support hair quality by helping 
to maintain healthy connective tissue in the dermis, healthy women and men”, and “bioavailable 
silicon form, silicon is an essential element for normal structure of connective tissues such as skin, 
hair, joints, bone and blood vessels”. The Panel assumes that the target population is the general 
population. 
Collagen is a structural component of several tissues in the body including bone, cartilage, gums, skin, 
tendons and blood vessels. 
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the contribution to normal formation of collagen and 
connective tissue.  
The Panel considers that contribution to normal formation of collagen and connective tissue is a 
beneficial physiological effect. 
2.6. Maintenance of normal bone (ID 287, 335, 1652, 1718, 1945) 
The claimed effects are “silicon is required for normal bone and connective tissue formation”, 
“maintenance and promotion of healthy connective tissue in bone by stimulating bone collagen 
synthesis”, “essential part of the connective tissues, skin and hair”, “maintenance and promotion of 
healthy connective tissue in bone by stimulating bone collagen synthesis, healthy women and men”, 
and “bioavailable silicon form, silicon is an essential element for normal structure of connective 
tissues such as skin, hair, joints, bone and blood vessels”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal bone. 
The Panel considers that maintenance of normal bone is a beneficial physiological effect. 
2.7. Maintenance of normal joints (ID 1405, 1652, 1945) 
The claimed effects are “stability of the connective/cell tissue; strengthening the joint cartilage and 
the intervertebral disks, protection against”, “essential part of the connective tissues, skin and hair”, 
and “bioavailable silicon form, silicon is an essential element for normal structure of connective 
tissues such as skin, hair, joints, bone and blood vessels”. The Panel assumes that the target 
population is the general population. 
Silicon related health claims 
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In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal joints. 
The Panel considers that maintenance of normal joints is a beneficial physiological effect. 
2.8. Maintenance of normal appearance and elasticity of the skin (ID 288, 333)  
The claimed effects are “normal skin, hair and nails”, and “maintenance and promotion of healthy 
connective tissue in skin by stimulating collagen synthesis in the dermis”. The Panel assumes that the 
target population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of the normal appearance and elasticity of the skin. The Panel notes that the evidence 
provided does not establish that changes in the appearance or elasticity of the skin relate to changes in 
skin function. 
The Panel considers that the claim does not refer to a function of the body as required by Regulation 
(EC) No 1924/2006. 
2.9. Contribution to normal formation of hair and nails (ID 334, 1652, 1719) 
The claimed effects are “helps support hair quality by helping to maintain healthy connective tissue in 
the dermis”, “essential part of the connective tissues, skin and hair”, and “helps support hair quality 
by helping to maintain healthy connective tissue in the dermis, healthy women and men”. The Panel 
assumes that the target population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
contribution to normal formation of hair and nails. 
The Panel considers that contribution to normal formation of hair and nails is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
Silicon is considered an ultra-trace element for which a functional role in humans has not been 
identified. As the essentiality of silicon for humans has not been established, a dietary reference value 
for silicon has not been set (IoM, 2000). 
A number of narrative reviews on the health effects of silicon containing no original data for a 
scientific evaluation, post-mortem studies in humans assessing the content of silicon in various tissues 
(e.g. blood vessels), and human intervention studies on silicon supplementation for the treatment of 
acne were provided. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claims.  
The vast majority of the references provided for the scientific substantiation of the claims reported on 
animal studies which addressed the effects of silicon-free diets and/or the effects of reintroducing 
silicon into the diet on the structure and morphology of various tissues and/or organs, including 
collagen and bone. The Panel considers that evidence provided in animal studies is not sufficient to 
predict the occurrence of an effect of silicon withdrawal or silicon intake in humans. 
3.1. Protection against aluminium accumulation in the brain (ID 290) 
In one intervention study, patients with Alzheimer's disease were asked to drink 1.5 L of a silicic 
acid-rich mineral water each day for five days (Exley et al., 2006). Patients’ urinary excretion of 
Silicon related health claims 
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aluminium was determined pre- and post-intervention. The Panel notes that no measures of aluminium 
retention in the body or accumulation in the brain were undertaken. The Panel considers that no 
conclusions can be drawn from this study for the scientific substantiation of the claim. 
One epidemiological study examined the association between silicon dioxide (silica) and aluminium 
concentrations in drinking water and the risk of cognitive impairment using data from a 
population-based survey in 3,777 French subjects aged 65 years and older (Jacqmin-Gadda et al., 
1996). In an eight-year follow up of the same cohort, the relationship between aluminium and silica 
concentrations in drinking water and the risk of dementia and Alzheimer's disease was investigated 
(Rondeau et al., 2000). A further epidemiological study explored the association between the 
composition of drinking water and cognitive function and the risk of Alzheimer's disease in women 
taking part in the Epidemiology of Osteoporosis (EPIDOS) study (n=7,598) (Gillette-Guyonnet et al., 
2005). The Panel notes that no endpoint directly related to aluminium accumulation in the brain was 
measured in these epidemiological studies. The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claim.  
One animal study examined the effect of silicon supplementation on tissue aluminium retention in 
rats, and one in vitro study examined the chemistry of aluminium binding by silicic acid. The Panel 
considers that evidence provided in animal and in vitro studies is not sufficient to predict the 
occurrence of an effect of silicon consumption on protection against aluminium accumulation in the 
brain in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of silicon and protection against aluminium accumulation in the brain. 
3.2. Contribution to normal formation of collagen and connective tissue (ID 287, 288, 333, 
334, 335, 1405, 1652, 1718, 1719, 1945) 
No evidence has been provided that silicon plays a role in collagen formation in humans, and no 
human studies which addressed the effects of silicon intake on collagen or connective tissue 
formation have been provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of silicon and contribution to normal formation of collagen and connective tissue.  
3.3. Maintenance of normal bone (ID 287, 335, 1652, 1718, 1945) 
One human retrospective study on intramuscular administration of silicon on bone mineral density 
(BMD) was provided (Eisinger and Clairet, 1993). The Panel notes that the intra-muscular route is not 
relevant to human nutrition. One abstract reporting on a human intervention study on the effects of 
oral consumption of silicon on bone turnover and BMD, and one abstract reporting on a human 
observational study on the association between dietary silicon consumption and BMD, which 
included insufficient data for a full scientific evaluation were also provided (Jugdaohsingh et al., 
2003; Spector et al., 2005). The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
One human intervention study on the effects of silicon consumed orally at doses of 5.5 g/day for 
20 days per month for three months (n=14) vs. no intervention (n=15) on trabecular bone volume 
measured by bone biopsy was provided (Schiano et al., 1979). The Panel notes that the study was not 
placebo-controlled, that it is unclear whether the subjects were randomly assigned to the intervention 
and control groups, and that no information was provided about blinding or the statistical analyses 
performed. The Panel notes the poor methodological reporting and considers that no conclusions can 
be drawn from this study for the scientific substantiation of the claim. 
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One randomised, double-blind, placebo-controlled human intervention study investigated the effects 
of silicon as choline-stabilised orthosilicic acid (ch-OSA) in association with calcium (1,000 mg/day) 
and cholecalciferol (20 g/day), administered for 12 months, on BMD and markers of bone turnover 
in 184 osteopenic post-menopausal women (Spector et al., 2008). Women were randomly assigned to 
consume ch-OSA at doses of 3, 6 and 12 mg silicon/day (3, 6 and 12 drops) or placebo (3, 6 or 12 
drops to mimic the intervention) plus calcium and cholecalciferol. BMD was measured by dual-
energy x-ray absorptiometry (DXA) at the beginning and end of the study, whereas markers of bone 
formation (osteocalcin (OC), bone specific alkaline phosphatase (BAP) and procollagen type I N-
terminal propeptide (PINP)) and of bone resorption (deoxypyridoline (DPD) and C-terminal 
telopeptide of type I collagen (CTX-I)) were assessed at baseline and at 6 and 12 months of the study. 
It was estimated that 175 subjects needed to be recruited to observe a 25 % difference between ch-
OSA and placebo groups on markers of bone turnover with an α<0.05 and a power of 85 %, taking 
into account a drop-out rate of 20 %. Statistical analysis and baseline characteristics of subjects were 
provided for the population of completers only (n=136, n=37 in the placebo group and n=33 in each 
ch-OSA group). Post-hoc sub-group analyses were carried out for changes in femoral BMD in women 
with a femoral BMD T-score <-1. The Panel notes that these post-hoc comparisons were not 
pre-planned, and that no adjustments for multiple testing were performed. Intervention and placebo 
groups were not comparable at baseline for markers of bone turnover or BMD. No significant 
differences in BMD changes between the intervention and placebo groups were observed during the 
12-month intervention. Changes in markers of bone turnover were not significantly different between 
groups (OC, BAP, DPD), except for PINP, which at 12 months was significantly lower in the 6 and 12 
mg ch-OSA groups than in the placebo group. The Panel notes that this study does not show an effect 
of ch-OSA on BMD in post-menopausal women.  
One cross-sectional, population-based study including 2,847 subjects (306 pre-menopausal women, 
1,325 post-menopausal women, 1,295 men) from the Framingham Offspring Cohort assessed the 
association between dietary silicon intake and BMD at the hip and lumbar spine (Jugdaohsingh et al., 
2004). Dietary intake of silicon was assessed using a food frequency questionnaire and BMD was 
investigated by DXA. After adjustment for confounders known to affect BMD (age, height, body 
mass index, physical activity, calcium and vitamin D intakes, and certain medications), silicon intakes 
correlated positively with BMD at four hip sites in men and pre-menopausal women, but not in 
post-menopausal women, whereas no significant association was found between silicon intake and 
BMD in the lumbar spine for any group. The Panel notes that the findings of this cross-sectional study 
on the association between silicon intakes and BMD were inconsistent, and that no suitable 
explanation for a differential effect of silicon in different population sub-groups and in different bone 
sites has been provided. 
The Panel notes that no human intervention studies addressing the effects of silicon intakes on BMD 
in men or pre-menopausal women have been submitted, and that no evidence for a mechanism by 
which silicon could exert an effect on bone has been provided.  
In weighing the evidence, the Panel took into account that a randomised, double-blind, 
placebo-controlled human intervention study did not show an effect of silicon administration (as 
ch-OSA) on BMD at any site in post-menopausal women, that the findings of a cross-sectional study 
on the association between silicon intakes and BMD were inconsistent, and that no evidence for a 
mechanism by which silicon could exert the claimed effect has been provided. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of silicon and maintenance of normal bone.  
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3.4. Maintenance of normal joints (ID 1405, 1652, 1945) 
No evidence has been provided that silicon plays a role in the maintenance of normal joints in 
humans, and no human studies which addressed the effects of silicon intake on joint function have 
been provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of silicon and maintenance of normal joints. 
3.5. Contribution to normal formation of hair and nails (ID 334, 1652, 1719) 
In an open label, uncontrolled intervention study (Lassus, 1993), the effects of colloidal silicic acid, 
taken orally (10 mL once daily) and applied topically to the face for 10 min during 90 days, on 
“thickness and turgor of the skin, wrinkles and condition of the hair and nails” in 50 women with 
“biologically aged” skin and fragile or thin hair, or brittle nails, were investigated. The Panel notes the 
uncontrolled nature of the study and considers that no conclusions can be drawn from it for the 
scientific substantiation of the claim. 
One randomised, double-blind, placebo-controlled intervention study (Wickett et al., 2007) 
investigated the effects of silicon as ch-OSA (10 mg/day, n=24) taken orally for nine months vs. 
placebo (microcrystalline cellulose, n=24) on hair morphology and hair tensile properties in women 
(18-65 years) with fine hair as assessed at baseline by a professional hairdresser on a visual analogue 
scale (3-point scale: fine, normal and thick). Outcome measures for hair tensile properties (n=5), both 
within groups and between groups, were assessed using Wilcoxon tests for paired comparisons and 
Mann-Whitney U tests for independent samples, respectively, in completers only (22 and 23 in the 
intervention and placebo groups, respectively). In addition, several morphology parameters were 
determined but only changes in the cross-sectional area of the hair, in the minor axis and in the major 
axis are reported. The Panel notes that no power calculations were performed, that the primary 
outcome measure was not identified, that a high number of outcome variables were tested, and that 
adjustments for multiple comparisons were not performed. The Panel considers that because of the 
important methodological limitations identified no conclusions can be drawn from this study for the 
scientific substantiation of the claim.  
One randomised, double blind, placebo controlled human intervention study (Barel et al., 2005) 
investigated the effects of silicon as ch-OSA (10 mg/day, n=25) taken orally for 20 weeks vs. placebo 
(microcrystalline cellulose, n=25) on skin, hair and nail parameters in women (40-65 years) with 
“clear signs of photo-aging of facial skin” (not better defined). A total of five outcome measures were 
related to the skin, whereas the outcome measure for hair and nails was the degree of brittleness on a 
4-point scale (no brittle hair/nails; slight, moderate and severe brittleness). Changes in all of the 
parameters were assessed both within groups and between groups using Wilcoxon tests for paired 
comparisons and Mann-Whitney U tests for independent samples, respectively. The Panel notes that 
no power calculations were performed, that the primary outcome was not identified, that a high 
number of outcome variables were tested, and that adjustment for multiple comparisons was not 
performed. The Panel also notes that it is not stated who or how many “assessors” evaluated the study 
subjects for brittleness of hair and nails, or which criteria were used for the evaluation. The Panel 
considers that because of the important methodological limitations identified no conclusions can be 
drawn from this study for the scientific substantiation of the claim.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of silicon and contribution to the normal formation of hair and nails. 
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CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, silicon, which is the subject of the health claims, is sufficiently 
characterised. 
Protection against aluminium accumulation in the brain (ID 290) 
 The claimed effect is “mental health”. The target population is assumed to be the general 
population. In the context of the proposed wordings, it is assumed that the claimed effect 
refers to protection against aluminium accumulation in the brain. Protection against 
aluminium accumulation in the brain might be a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of silicon 
and protection against aluminium accumulation in the brain. 
“Cardiovascular health” (ID 289) 
 The claimed effect is “cardiovascular health”. The target population is assumed to be the 
general population. The claimed effect has not been sufficiently defined. 
 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
Forming a protective coat on the mucous membrane of the stomach (ID 345) 
 The claimed effect is “gut health”. The target population is assumed to be the general 
population. From the clarifications provided by Member States, it is assumed that the claimed 
effect refers to forming a protective coat on the mucous membrane of the stomach. No 
evidence has been provided to indicate the context in which the claimed effect could be 
considered to be a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of silicon 
and a beneficial physiological effect related to forming a protective coat on the mucous 
membrane of the stomach. 
Neutralisation of gastric acid (ID 345) 
 The claimed effect is “gut health”. The target population is assumed to be the general 
population. From the clarifications provided by Member States, it is assumed that the claimed 
effect refers to the neutralisation of gastric acid. The evidence provided does not establish 
that the neutralisation of gastric acid is a beneficial physiological effect for the general 
population.  
 A cause and effect relationship has not been established between the consumption of silicon 
and a beneficial physiological effect for the general population related to the neutralisation of 
gastric acid.  
Contribution to normal formation of collagen and connective tissue (ID 287, 288, 333, 334, 335, 
1405, 1652, 1718, 1719, 1945) 
 The claimed effects are “silicon is required for normal bone and connective tissue formation”, 
“normal skin, hair and nails”, “maintenance and promotion of healthy connective tissue in 
skin by stimulating collagen synthesis in the dermis”, “helps support hair quality by helping 
to maintain healthy connective tissue in the dermis”, “maintenance and promotion of healthy 
connective tissue in bone by stimulating bone collagen synthesis”, “stability of the 
connective/cell tissue; strengthening the joint cartilage and the intervertebral disks, protection 
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against”, “essential part of the connective tissues, skin and hair”, “maintenance and 
promotion of healthy connective tissue in bone by stimulating bone collagen synthesis, 
healthy women and men”, “helps support hair quality by helping to maintain healthy 
connective tissue in the dermis, healthy women and men”, and “bioavailable silicon form, 
silicon is an essential element for normal structure of connective tissues such as skin, hair, 
joints, bone and blood vessels”. The target population is assumed to be the general 
population. In the context of the proposed wordings and clarifications provided by Member 
States, it is assumed that the claimed effects refer to contribution to normal formation of 
collagen and connective tissue. Contribution to normal formation of collagen and connective 
tissue is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of silicon 
and contribution to normal formation of collagen and connective tissue. 
Maintenance of normal bone (ID 287, 335, 1652, 1718, 1945) 
The claimed effects are “silicon is required for normal bone and connective tissue formation”, 
“maintenance and promotion of healthy connective tissue in bone by stimulating bone 
collagen synthesis”, “essential part of the connective tissues, skin and hair”, “maintenance 
and promotion of healthy connective tissue in bone by stimulating bone collagen synthesis, 
healthy women and men”, and “bioavailable silicon form, silicon is an essential element for 
normal structure of connective tissues such as skin, hair, joints, bone and blood vessels”. The 
target population is assumed to be the general population. In the context of the proposed 
wordings, it is assumed that the claimed effects refer to the maintenance of normal bone. 
Maintenance of normal bone is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of silicon 
and maintenance of normal bone. 
Maintenance of normal joints (ID 1405, 1652, 1945) 
 The claimed effects are “stability of the connective/cell tissue; strengthening the joint 
cartilage and the intervertebral disks, protection against”, “essential part of the connective 
tissues, skin and hair”, and “bioavailable silicon form, silicon is an essential element for 
normal structure of connective tissues such as skin, hair, joints, bone and blood vessels”. The 
target population is assumed to be the general population. In the context of the proposed 
wordings, it is assumed that the claimed effects refer to the maintenance of normal joints. 
Maintenance of normal joints is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of silicon 
and maintenance of normal joints. 
Maintenance of normal appearance and elasticity of the skin (ID 288, 333) 
 The claimed effects are “normal skin, hair and nails”, and “maintenance and promotion of 
healthy connective tissue in skin by stimulating collagen synthesis in the dermis”. The target 
population is assumed to be the general population. In the context of the proposed wordings, 
it is assumed that the claimed effects refer to the maintenance of normal appearance and 
elasticity of the skin.  
 The claim does not refer to a function of the body as required by Regulation (EC) No 
1924/2006. 
Contribution to normal formation of hair and nails (ID 334, 1652, 1719) 
 The claimed effects are “helps support hair quality by helping to maintain healthy connective 
tissue in the dermis”, “essential part of the connective tissues, skin and hair”, and “helps 
support hair quality by helping to maintain healthy connective tissue in the dermis, healthy 
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women and men”. The target population is assumed to be the general population. In the 
context of the proposed wordings, it is assumed that the claimed effects refer to the 
contribution to normal formation of hair and nails. Contribution to normal formation of hair 
and nails is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of silicon 
and contribution to the normal formation of hair and nails. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1074, 
EFSA-Q-2008-1075, EFSA-Q-2008-1076, EFSA-Q-2008-1077, EFSA-Q-2008-1120, EFSA-Q-2008-
1121, EFSA-Q-2008-1122, EFSA-Q-2008-1132, EFSA-Q-2008-2142, EFSA-Q-2008-2388, EFSA-Q-
2008-2454, EFSA-Q-2008-2455, EFSA-Q-2008-2678). The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
8
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
9
  
Foods are commonly involved in many different functions
10
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
8 OJ L12, 18/01/2007 
9 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
10 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to silicon, including conditions of use from similar claims, 
as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
287 Silicon Silicon is required for 
normal bone and 
connective tissue 
formation 
Silicon is required for normal bone and 
connective tissue formation. 
Conditions of use 
- Guidance level is 700mg/day or less from supplements (FSA). 
Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006 
- 5-10 mg of OSA 
Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006. 
- Food supplement with 196-588 mg (15-45 ml) of silicon in the daily dose 
- Food supplement with 100mg of silicon in the daily dose 
- Silicon acid gel 
- Amount of comsumption: ab 20 mg/l Slizium 
- Daily intake of 6-10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 3-5 mg Si in the morning and 3-5 mg Si in the evening. Healthy females and males. 
ID Food or Food constituent Health Relationship Proposed wording 
288 Silicon and Silicon (as 
stabilized 0ligomeric 
orthosilicic acid (OSA) 
Normal skin, hair and 
nails. 
Silicon is required for healthy skin, hair 
and nails. 
Silicon is beneficial for collagen 
formation in the skin; Silicon reduces the 
appearance of wrinkles as it stimulates 
the formation of collagen and helps 
improve skin elasticity;  
Conditions of use 
- Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006 
- Food supplements with at least 100mg of silicon in the daily dose 
- Silicon acid gel with 196-588mg of silicon in the daily serving 
Product contains only silicon oxide and water. 
- Silicon acid gel food supplement with 196-588mg of silicon in the daily dose 
Product contains only silicon oxide and water. 
- 363 mg per day 
- Daily intake of 10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening. Healthy females and males. 
Silicon related health claims 
 
24 EFSA Journal 2011;9(6):2259 
- Daily intake of 10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening 
ID Food or Food constituent Health Relationship Proposed wording 
289 Silicon (as stabilized 
0ligomeric orthosilicic 
acid (OSA) 
Cardiovascular health Silicon is beneficial for cardiovascular 
health;  
Silicon supports the health of the 
cardiovascular system; Silicon helps to 
maintain the health of blood vessels 
Conditions of use 
- 5-10 mg of OSA 
Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006. 
- Food supplement with at least 100mg of silicon in the daily dose 
Comments from Member States 
No further clarification received 
ID Food or Food constituent Health Relationship Proposed wording 
290 Silicon (as stabilized 
oligomeric orthosilicic 
acid (OSA) 
Mental health Silicon helps protect the brain; Silicon 
reduces aluminium accumulation in the 
brain 
Conditions of use 
- 5- 10 mg of OSA 
- Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
333 cholinestabilized 
orthosilicic acid (ch-OSA) 
(The mineral silicon (Si) is 
present in water as 
orthosilicic acid (OSA), 
ch-OSA is a stabilized and 
concentrated source of 
orthosilicic acid) 
Maintenance and 
promotion of healthy 
connective tissue in 
skin by stimulating 
collagen synthesis in 
the dermis. 
 helps reduce the appearance 
of wrinkles 
- helps improve skin elasticity 
Conditions of use 
- Daily intake of 10 mg silicon (Si) in the form of cholinestabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening 
Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006. 
- Daily intake of 10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening 
ID Food or Food constituent Health Relationship Proposed wording 
334 cholinestabilized Helps support - helps improve hair thickness 
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orthosilicic acid (ch-OSA) 
(The mineral silicon (Si) is 
present in water as 
orthosilicic acid (OSA), 
ch-OSA is a stabilized and 
concentrated source of 
orthosilicic acid) 
hairquality by helping 
to maintain healthy 
connective tissue in the 
dermis. 
- helps maintain hair strength and hair 
elasticity 
Conditions of use 
- Daily intake of 10 mg silicon (Si) in the form of cholinestabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening. Healthy females and males. 
Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006. 
- Daily intake of 10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening.  
- Daily intake of 5-10 mg of stabilized Oligomeric orthosilicic acid 
ID Food or Food constituent Health Relationship Proposed wording 
335 cholinestabilized 
orthosilicic acid (ch-OSA) 
(The mineral silicon (Si) is 
present in water as 
orthosilicic acid (OSA), 
ch-OSA is a stabilized and 
concentrated source of 
orthosilicic acid) 
Maintenance and 
promotion of healthy 
connective tissue in 
bone by stimulating 
bone collagen 
synthesis. 
 
 helps support bone quality by 
stimulating bone collagen 
- helps maintain strong bones 
 
Conditions of use 
- Daily intake of 6-10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 3-5 mg Si in the morning and 3-5 mg Si in the evening.  
- Daily intake of 6-10 mg silicon (Si) in the form of cholinestabilized orthosilicic acid (ch-
OSA); 3-5 mg Si in the morning and 3-5 mg Si in the evening. Healthy females and males. 
Must meet minimum requirements for use of the claim "source of [name of vitamin/s] and/or 
[name of mineral/s]" as per Annex to Regulation 1924/2006. 
- Daily intake of 5-10 mg of stabilized Oligomeric orthosilicic acid 
ID Food or Food constituent Health Relationship Proposed wording 
345 Silicon 
 
Gut health 
Clarification provided 
Forms a protecting coat 
on the mucous 
membrane of the 
stomach 
Neutralizes stomach 
acids thus calming 
irritated stomach 
For stomach health. 
Sooths the stomach 
Protects the stomach’s mucous 
membranes. 
 
Conditions of use 
- Food supplement with silicon starting from 100mg in the daily dose 
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- Food supplement with colloid silicon (silicon oxide dispersed in water) content of 3g/100g, 
450-1350mg/daily dose 
Comments from Member States 
Health relationship defined 
ID Food or Food constituent Health Relationship Proposed wording 
1405 Mineralwasser/ 
Kieselsäure (Silizium) 
Clarification provided 
Mineral water/silicic acid 
(silicon) 
Festigkeit des 
Bindegewebes/ 
Zellgewebes 
Clarification provided 
stability of the 
connective/cell tissue; 
strengthening the joint 
cartilage and the 
intervertebral disks; 
Protection against  
[In german : ] stärkt/festigt das 
Bindegewebe 
Clarification provided 
–strengthens/stabilizes the connective 
tissue  
Conditions of use 
- Amount of consumption: ab 20 mg/l Slizium 
ID Food or Food constituent Health Relationship Proposed wording 
1652 Silica / Silicious earth Essential part of the 
connective tissues, skin 
and hair 
Plays an important part in the connective 
tissue/ helps maintain healthy hair, skin 
and nails/ helps strengthen skin, hair and 
nails/ helps maintain healthy skin, joints 
and bone and strong hair and nails/ 
traditionally used to contribute to the 
condition 
Conditions of use 
- Typical intake: 20-500 mg slicon per day 
- No RDA dose defined yet. Typical intake: 20-50 mg silicon per day 
- 500 mg/day  
ID Food or Food constituent Health Relationship Proposed wording 
1718 choline-stabilized 
orthosilicic acid (ch-OSA)  
(The mineral silicon is 
present in water as 
orthosilicic acid; ch-OSA 
is a stabilized and 
concentrated source of 
orthosilicic acid) 
Maintenance and 
promotion of healthy 
connective tissue in 
bone by stimulating 
bone collagen 
synthesis. 
Healty women and 
men. 
- helps support bone quality by 
stimulating bone collagen 
- helps maintain strong bones 
- helps maintain bone mineral density 
- helps maintain healthy bones 
Conditions of use 
- Daily intake of 6-10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 3-5 mg Si in the morning and 3-5 mg Si in the evening 
- Daily intake of 10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening 
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ID Food or Food constituent Health Relationship Proposed wording 
1719 choline-stabilized 
orthosilicic acid (ch-OSA)  
(The mineral silicon is 
present in water as 
orthosilicic acid; ch-OSA 
is a stabilized and 
concentrated source of 
orthosilicic acid) 
Helps support hair 
quality by helping to 
maintain healthy 
connective tissue in the 
dermis. 
Healthy women and 
men. 
helps improve hair thickness 
- helps maintain hair strength and hair 
elasticity 
- helps improve hair volume 
- helps maintain healthy hair 
Conditions of use 
- Daily intake of 10 mg silicon (Si) in the form of choline-stabilized orthosilicic acid (ch-
OSA); 5 mg Si in the morning and 5 mg Si in the evening.  
ID Food or Food constituent Health Relationship Proposed wording 
1945 Monométhylsilanetriol: 
other substance with 
nutritionnal or 
physiological effects 
Bioavailable Silicon 
form. Silicon is an 
essential element for 
normal structure of 
connective tissues such 
as skin, hair, joints, 
bone and blood vessels 
Contributes to maintenance of healthy 
skin, joints and bone.  
-Contributes to maintenance of strong 
hairs and nails. 
-Contributes to the structure of blood 
vessels. 
-Supports mobility and flexibility by 
contribution to the structure of articular 
cartilage  
Conditions of use 
- Typical intake: 20-500 mg silicon per day 
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GLOSSARY AND ABBREVIATIONS 
BAP  Bone specific alkaline phosphatase 
BMD  Bone mineral density 
ch-OSA choline-stabilised orthosilicic acid 
CTX-I  C-terminal telopeptide of type I collagen 
DPD  Deoxypyridoline 
DXA  Dual-energy x-ray absorptiometry 
EPIDOS Epidemiology of osteoporosis 
OC  Osteocalcin 
OSA  Orthosilicic acid 
PINP  Procollagen type I N-terminal propeptide 
 
